Single-nucleotide Polymorphism (snp) Targeting Therapies for the Treatment of Huntington's Disease

The present invention relates to the discovery of (SNPs) significantly associated with Huntington's disease (HD). The present invention utilizes RNA silencing technology (e.g. RNAi) against such SNPs optimally combined with select additional SNP targeting silencing agents, thereby resulting in an effective treatment of significantly- sized patient populations. Silencing agents having enhanced discriminatory properties are also featured.

Patents:
WO 2,010,118,263

Inventor(s): ARONIN NEIL [US]; PFISTER EDITH [US]

Type of Offer: Sale



« More Genetics Patents

---